To the best of our knowledge, this is the first survey of ErbB2-positivity results obtained from a large sample of patients to indicate that the prevalence of ErbB2-positive breast cancer in Asia is similar to that in Western countries (range, 18%-25%).4,5 Notably, this finding is based on Asian data that were obtained using the more robust assessment methods, IHC3+ and FISH.32,33 Because the prevalence of ErbB2-positive tumors is not apparently higher in Asia, alternative reasons for the low breast cancer survival rate should be explored. Here, ERBB2 is linked to breast cancer.